Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • New Therapeutic Targets in Cardiovascular Diseases (Upcoming)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI116352

Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization.

J G Pickering, L Weir, J Jekanowski, M A Kearney, and J M Isner

Department of Medicine (Cardiology), St. Elizabeth's Hospital, Tufts University School of Medicine, Boston, Massachusetts 02135.

Find articles by Pickering, J. in: JCI | PubMed | Google Scholar

Department of Medicine (Cardiology), St. Elizabeth's Hospital, Tufts University School of Medicine, Boston, Massachusetts 02135.

Find articles by Weir, L. in: JCI | PubMed | Google Scholar

Department of Medicine (Cardiology), St. Elizabeth's Hospital, Tufts University School of Medicine, Boston, Massachusetts 02135.

Find articles by Jekanowski, J. in: JCI | PubMed | Google Scholar

Department of Medicine (Cardiology), St. Elizabeth's Hospital, Tufts University School of Medicine, Boston, Massachusetts 02135.

Find articles by Kearney, M. in: JCI | PubMed | Google Scholar

Department of Medicine (Cardiology), St. Elizabeth's Hospital, Tufts University School of Medicine, Boston, Massachusetts 02135.

Find articles by Isner, J. in: JCI | PubMed | Google Scholar

Published April 1, 1993 - More info

Published in Volume 91, Issue 4 on April 1, 1993
J Clin Invest. 1993;91(4):1469–1480. https://doi.org/10.1172/JCI116352.
© 1993 The American Society for Clinical Investigation
Published April 1, 1993 - Version history
View PDF
Abstract

We evaluated the proliferative activity of human atherosclerotic lesions associated with active symptoms of ischemia, by assessing the expression of the proliferating cell nuclear antigen (PCNA). We confirmed in vitro that PCNA, an essential component of the DNA synthesis machinery, is selectively expressed in proliferating human vascular smooth muscle cells. 37 atherosclerotic lesions (18 primary and 19 restenotic) retrieved by directional atherectomy from either coronary or peripheral arteries were then studied for the expression of PCNA, using in situ hybridization or immunohistochemistry. Among plaques studied by in situ hybridization, 7 out of 11 primary and 11 out of 11 restenotic lesions contained PCNA-positive cells. The mean rate of proliferation (percent of PCNA-positive cells) was 7.2 +/- 10.8% in primary lesions and 20.6 +/- 18.2% in restenotic lesions (P < 0.05). Among specimens studied by immunohistochemistry, five out of seven primary and eight out of eight restenotic lesions contained proliferating cells. The mean rate of proliferation was again higher in the restenotic (15.2 +/- 13.6%) than primary (3.6 +/- 3.5%) lesions (P < 0.05). Proliferating cells were detected as late as 1 yr after angioplasty. We conclude that cellular proliferation is a feature of atherosclerotic lesions which are associated with symptoms of ischemia, but that it is more prominent in restenosis compared to primary lesions. These findings have implications for therapies aimed at limiting lesion growth, particularly after percutaneous revascularization.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1469
page 1469
icon of scanned page 1470
page 1470
icon of scanned page 1471
page 1471
icon of scanned page 1472
page 1472
icon of scanned page 1473
page 1473
icon of scanned page 1474
page 1474
icon of scanned page 1475
page 1475
icon of scanned page 1476
page 1476
icon of scanned page 1477
page 1477
icon of scanned page 1478
page 1478
icon of scanned page 1479
page 1479
icon of scanned page 1480
page 1480
Version history
  • Version 1 (April 1, 1993): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts